Markets

Reported Sunday, Genentech’s Divarasib Lowers Death Risk 44% In Phase III Krascendo 1 With Fewer TRAE Discontinuations (4.8% Versus 11.7%) Than Sotorasib Or Adagrasib In Previously Treated KRAS G12C NSCLC

Oct 26, 2026 · 03:28 AM ET· updated 1h ago

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo

Why It Matters

Genentech's new cancer drug worked better than older similar drugs. Fewer patients stopped taking it because of side effects, which matters for real-world use.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

RHHBY61.17

+1.55 (+2.60%)

RHHVF484.28

+17.22 (+3.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.